BUSPAR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Buspar, and what generic alternatives are available?
Buspar is a drug marketed by Bristol Myers Squibb and is included in two NDAs.
The generic ingredient in BUSPAR is buspirone hydrochloride. There are nineteen drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the buspirone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Buspar
A generic version of BUSPAR was approved as buspirone hydrochloride by IMPAX LABS INC on March 28th, 2001.
Summary for BUSPAR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 111 |
| Clinical Trials: | 20 |
| Patent Applications: | 646 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | BUSPAR at DailyMed |
Recent Clinical Trials for BUSPAR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Spaulding Rehabilitation Hospital | Phase 2 |
| University of Louisville | Early Phase 1 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Early Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for BUSPAR
US Patents and Regulatory Information for BUSPAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | BUSPAR | buspirone hydrochloride | CAPSULE;ORAL | 021190-001 | Dec 20, 2000 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Bristol Myers Squibb | BUSPAR | buspirone hydrochloride | TABLET;ORAL | 018731-003 | Apr 22, 1996 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Bristol Myers Squibb | BUSPAR | buspirone hydrochloride | CAPSULE;ORAL | 021190-004 | Dec 20, 2000 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Bristol Myers Squibb | BUSPAR | buspirone hydrochloride | TABLET;ORAL | 018731-004 | Apr 22, 1996 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BUSPAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | BUSPAR | buspirone hydrochloride | CAPSULE;ORAL | 021190-003 | Dec 20, 2000 | ⤷ Try a Trial | ⤷ Try a Trial |
| Bristol Myers Squibb | BUSPAR | buspirone hydrochloride | CAPSULE;ORAL | 021190-004 | Dec 20, 2000 | ⤷ Try a Trial | ⤷ Try a Trial |
| Bristol Myers Squibb | BUSPAR | buspirone hydrochloride | TABLET;ORAL | 018731-004 | Apr 22, 1996 | ⤷ Try a Trial | ⤷ Try a Trial |
| Bristol Myers Squibb | BUSPAR | buspirone hydrochloride | TABLET;ORAL | 018731-001 | Sep 29, 1986 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for BUSPAR
See the table below for patents covering BUSPAR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 533115 | ⤷ Try a Trial | |
| Canada | 1133393 | COMPRIME MULTI-SECABLE (MULTI-FRACTIONABLE TABLET STRUCTURE) | ⤷ Try a Trial |
| Kenya | 2691 | HETEROCYCLIC AZASPIROALKANEDIONES | ⤷ Try a Trial |
| Austria | A160880 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
